CDT Equity Inc CDT
๐ Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-02-03 |
| Shares Out. | 660,000 |
| Website | cdtequity.com/ โ |
| Phone | 13026587581 |
| Employees | 4 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.6M |
| Free Cash Flow | -$11.9M |
| Total Assets | $126.7M |
| Total Liabilities | $23.6M |
| Equity | $103.1M |
About CDT Equity Inc
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
CDT Equity Inc is a publicly traded company under the ticker symbol CDT on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
